CytoDyn (CYDY) Net Equity Issued and Repurchased (2010 - 2021)

CytoDyn's Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at $10.7 million for Q4 2021.

• Quarterly Net Equity Issued and Repurchased rose 970.0% year-over-year to $10.7 million in Q4 2021, while the trailing twelve-month figure through May 2022 was $11.7 million (changed N/A YoY) and the FY2022 annual result came in at $11.4 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased was $10.7 million for Q4 2021 at CytoDyn, up from $2.9 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $12.3 million in Q2 2020 and bottomed at $1.0 million in Q4 2020.
• A 3-year average of $7.2 million and a median of $7.5 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased tumbled 76.74% — and 2021, when it jumped 970.0%.
• CytoDyn's Net Equity Issued and Repurchased stood at $4.3 million in 2019, then tumbled by 76.74% to $1.0 million in 2020, then soared by 970.0% to $10.7 million in 2021.
• Business Quant data shows CYDY's Net Equity Issued and Repurchased at $10.7 million in Q4 2021, $2.9 million in Q3 2021, and $1.0 million in Q4 2020.